Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis

Archive ouverte

Renosi, Florian | Roggy, Anne | Giguelay, Ambre | Soret, Lou | Viailly, Pierre-Julien | Cheok, Meyling | Biichle, Sabeha | Angelot-Delettre, Fanny | Asnafi, Vahid | Macintyre, Elizabeth | Geffroy, Sandrine | Callanan, Mary | Petrella, Tony | Deconinck, Eric | Daguindau, Etienne | Harrivel, Véronique | Bouyer, Sabrina | Salaün, Véronique | Saussoy, Pascale | Feuillard, Jean | Fuseau, Pascal | Saas, Philippe | Adotévi, Olivier | Jardin, Fabrice | Ferrand, Christophe | Preudhomme, Claude | Colinge, Jacques | Roumier, Christophe | Garnache-Ottou, Francine

Edité par CCSD ; The American Society of Hematology -

International audience. Oncogenesis and ontogeny of blastic plasmacytoid dendritic cell neoplasm (BPDCN) remain uncertain, between canonical plasmacytoid dendritic cells (pDCs) and AXL+ SIGLEC6+ DCs (AS-DCs). We compared 12 BPDCN to 164 acute leukemia by Affymetrix HG-U133 Plus 2.0 arrays: BPDCN were closer to B-cell acute lymphoblastic leukemia (ALL), with enrichment in pDC, B-cell signatures, vesicular transport, deubiquitination pathways, and AS-DC signatures, but only in some cases. Importantly, 1 T-cell ALL clustered with BPDCN, with compatible morphology, immunophenotype (cCD3+ sCD3− CD123+ cTCL1+ CD304+), and genetics. Many oncogenetic pathways are deregulated in BPDCN compared with normal pDC, such as cell-cycle kinases, and importantly, the transcription factor SOX4, involved in B ontogeny, pDC ontogeny, and cancer cell invasion. High-throughput sequencing (HaloPlex) showed myeloid mutations (TET2, 62%; ASXL1, 46%; ZRSR2, 31%) associated with lymphoid mutations (IKZF1), whereas single-nucleotide polymorphism (SNP) array (Affymetrix SNP array 6.0) revealed frequent losses (mean: 9 per patient) involving key hematological oncogenes (RB1, IKZF1/2/3, ETV6, NR3C1, CDKN2A/B, TP53) and immune response genes (IFNGR, TGFB, CLEC4C, IFNA cluster). Various markers suggest an AS-DC origin, but not in all patients, and some of these abnormalities are related to the leukemogenesis process, such as the 9p deletion, leading to decreased expression of genes encoding type I interferons. In addition, the AS-DC profile is only found in a subgroup of patients. Overall, the cellular ontogenic origin of BPDCN remains to be characterized, and these results highlight the heterogeneity of BPDCN, with a risk of a diagnostic trap.

Consulter en ligne

Suggestions

Du même auteur

How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?

Archive ouverte | Garnache-Ottou, Francine | CCSD

International audience. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia for which we developed a nationwide network to collect data from new cases diagnosed in France. In a ret...

Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscape

Archive ouverte | Zalmaï, Loria | CCSD

International audience. Neoplasms involving plasmacytoid dendritic cells (pDC) include blastic pDC neoplasms (BPDCN) and other pDC proliferations, where pDC are associated with myeloid malignancies: most frequently ...

Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscape

Archive ouverte | Zalmaï, Loria | CCSD

International audience. Neoplasms involving plasmacytoid Dendritic Cells (pDCs) include Blastic pDC Neoplasms (BPDCN) and other pDC proliferations, where pDCs are associated with myeloid malignancies: most frequentl...

Chargement des enrichissements...